NYSE:BCR - C R Bard Stock Price, Price Target & More

$331.24 0.00 (0.00 %)

(As of 04/22/2018 04:00 PM ET)

Previous Close$331.24

Today's Range$331.24 - $331.24

52-Week Range$222.42 - $337.73

VolumeN/A

Average Volume679,456 shs

Market Capitalization$24.14 billion

P/E RatioN/A

Dividend Yield0.23%

Beta0.52

About C R Bard (NYSE:BCR)

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive BCR News and Ratings via Email

Sign-up to receive the latest news and ratings for BCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A

Sub-IndustryHealth Care Equipment

SectorN/A

SymbolNYSE:BCR

CUSIP06738310

Webwww.crbard.com

Phone+1-908-2778000

Debt

Debt-to-Equity Ratio0.57%

Current Ratio1.72%

Quick Ratio1.37%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio27.86

P/E Growth2.53

Sales & Book Value

Annual Sales$3.71 billion

Price / Sales6.50

Cash Flow$13.4760 per share

Price / Cash24.58

Book Value$22.78 per share

Price / Book14.54

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$531.40 million

Net Margins9.51%

Return on Equity19.39%

Return on Assets6.91%

Miscellaneous

Employees16,300

Outstanding Shares72,890,000

How to Become a New Pot Stock Millionaire

C R Bard (NYSE:BCR) Frequently Asked Questions

What is C R Bard's stock symbol?

C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."

How often does C R Bard pay dividends? What is the dividend yield for C R Bard?

C R Bard announced a quarterly dividend on Wednesday, October 11th. Stockholders of record on Friday, December 8th will be paid a dividend of $0.26 per share on Friday, December 29th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. View C R Bard's Dividend History.

How were C R Bard's earnings last quarter?

C R Bard Inc (NYSE:BCR) announced its quarterly earnings data on Wednesday, October, 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.06. The medical instruments supplier earned $989.80 million during the quarter, compared to analysts' expectations of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 EPS. View C R Bard's Earnings History.

What price target have analysts set for BCR?

7 brokers have issued 1-year target prices for C R Bard's stock. Their forecasts range from $265.00 to $337.00. On average, they expect C R Bard's share price to reach $310.60 in the next twelve months. View Analyst Ratings for C R Bard.

What are Wall Street analysts saying about C R Bard stock?

Here are some recent quotes from research analysts about C R Bard stock:

1. According to Zacks Investment Research, "In the last year, C. R. Bard has outperformed the broader industry trends with respect to price performance. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close in the fourth quarter of 2017. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters.However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well. Additionally, cutthroat competition in the hernia fixation and peripheral stent businesses are likely to dent growth. " (12/26/2017)
2. Needham & Company LLC analysts commented, "BCR’s 3Q17 revenue missed and EPS beat consensus and management raised its 2017 revenue and EPS guidance. Revenue growth slowed somewhat to 5.0% in 3Q17 from 6.4% in 2Q17 as three of four segments missed consensus. Revenue growth faced a 1.5% headwind, attributable to the impact from the hurricanes and a Surgical Sealant supply issue, both equally. We have maintained our revenue and EPS estimates." (10/26/2017)

Who are some of C R Bard's key competitors?

Some companies that are related to C R Bard include Orange (ORAN), Capital One (COF), John Deere (DE), Simon Property Group (SPG), Valero Energy (VLO), Royal Bank of Scotland Group (RBS), Mizuho Financial Group (MFG), Fiat Chrysler Automobiles (FCAU), Southern (SO), Halliburton (HAL), Prudential Financial (PRU), BHP Billiton (BBL), Ecopetrol (EC), Emerson Electric (EMR), Constellation Brands (STZ), Southern Copper (SCCO), Intercontinental Exchange (ICE) and Praxair (PX).

Who are C R Bard's key executives?

C R Bard's management team includes the folowing people:

Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)
John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)
James C. Beasley, Group President (Age 53)
Timothy P. Collins, Group President (Age 56)
John P. Groetelaars, Group President (Age 50)
Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)
Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)
John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)
Frank Lupisella Jr., Vice President, Controller (Age 56)
Betty D. Larson, Vice President - Human Resources (Age 41)

Has C R Bard been receiving favorable news coverage?

News articles about BCR stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. C R Bard earned a coverage optimism score of 0.16 on Accern's scale. They also assigned news stories about the medical instruments supplier an impact score of 47.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of C R Bard?

Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is C R Bard's stock price today?

One share of BCR stock can currently be purchased for approximately $331.24.

How big of a company is C R Bard?

C R Bard has a market capitalization of $24.14 billion and generates $3.71 billion in revenue each year. C R Bard employs 16,300 workers across the globe.

How can I contact C R Bard?

C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000.

MarketBeat Community Rating for C R Bard (BCR)

Community Ranking:		1.8 out of 5 ()
Outperform Votes:		280 (Vote Outperform)
Underperform Votes:		504 (Vote Underperform)
Total Votes:		784

MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days.

C R Bard (NYSE:BCR) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for C R Bard in the last 12 months. Their average twelve-month price target is $310.60, suggesting that the stock has a possible downside of 6.23%. The high price target for BCR is $337.00 and the low price target for BCR is $265.00. There are currently 8 hold ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.00	2.00	2.00	2.22
Ratings Breakdown:	0 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 0 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$310.60	$310.60	$301.3333	$282.2857
Price Target Upside:	6.23% downside	7.01% downside	9.78% downside	11.87% downside

C R Bard (NYSE:BCR) Consensus Price Target History

Price Target History for C R Bard (NYSE:BCR)

C R Bard (NYSE:BCR) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/6/2017	Barclays	Boost Price Target	Equal Weight	$245.00 -> $337.00	N/A
11/3/2017	Cowen	Reiterated Rating	Hold	$317.00	N/A
10/26/2017	Needham & Company LLC	Reiterated Rating	Hold		N/A
9/14/2017	Jefferies Group	Reiterated Rating	Hold	$317.00	Medium
7/11/2017	BMO Capital Markets	Reiterated Rating	Hold	$317.00	Low
4/26/2017	Raymond James	Downgrade	Strong-Buy -> Mkt Perform		Low
4/25/2017	Wells Fargo	Downgrade	Outperform -> Market Perform		Low
4/24/2017	Morgan Stanley	Downgrade	Overweight -> Equal Weight		Low
1/27/2017	JMP Securities	Boost Price Target		$240.00 -> $255.00	N/A
1/5/2017	UBS	Upgrade	Outperform -> Strong-Buy		N/A
9/15/2016	Evercore ISI	Initiated Coverage	Buy	$235.00	N/A
7/28/2016	Leerink Swann	Reiterated Rating	Market Perform	$240.00 -> $233.00	N/A
7/27/2016	JPMorgan Chase	Boost Price Target	Neutral	$214.00 -> $225.00	N/A
7/27/2016	Citigroup	Boost Price Target	Buy	$241.00 -> $265.00	N/A
7/27/2016	Deutsche Bank	Boost Price Target	Hold	$234.00 -> $240.00	N/A
7/8/2016	Bank of America	Downgrade	Buy -> Neutral		N/A
5/24/2016	Piper Jaffray	Reiterated Rating	Buy	$241.00	N/A

(Data available from 4/22/2016 forward)

C R Bard (NYSE:BCR) Earnings History and Estimates Chart

Earnings by Quarter for C R Bard (NYSE:BCR)

C R Bard (NYSE:BCR) Earnings Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$2.88	$2.88	$2.88
Q2 2018	1	$3.12	$3.12	$3.12
Q3 2018	1	$3.19	$3.19	$3.19

C R Bard (NYSE BCR) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/25/2017	Q3 2017	$2.96	$3.02	$990.64 million	$989.80 million	View	N/A
7/27/2017	Q2 2017	$2.84	$2.92	$976.53 million	$979.70 million	View	N/A
4/23/2017	Q1 2017	$2.65	$2.87	$916.15 million	$938.80 million	View	N/A
1/26/2017	Q416	$2.74	$2.77	$956.12 million	$967.10 million	View	Listen
10/25/2016	Q3	$2.55	$2.64	$931.66 million	$941.90 million	View	Listen
7/26/2016	Q2	$2.47	$2.54	$915.22 million	$931.50 million	View	Listen
4/27/2016	Q116	$2.17	$2.34	$845.77 million	$873.50 million	View	Listen
1/28/2016	Q415	$2.41	$2.43	$867.22 million	$870.80 million	View	Listen
10/22/2015	Q3	$2.24	$2.28	$852.93 million	$865.70 million	View	Listen
7/23/2015	Q2	$2.18	$2.27	$836.18 million	$859.80 million	View	Listen
4/23/2015	Q115	$2.07	$2.10	$813.36 million	$819.70 million	View	Listen
1/29/2015	Q414	$2.24	$2.29	$855.11 million	$867.20 million	View	Listen
10/22/2014	Q314	$2.10	$2.15	$819.20 million	$830.00 million	View	Listen
7/24/2014	Q214	$2.00	$2.06	$814.58 million	$827.10 million	View	Listen
4/22/2014	Q114	$1.86	$1.91	$787.10 million	$799.30 million	View	Listen
1/30/2014	Q413	$1.41	$1.42	$782.28 million	$791.30 million	View	Listen
10/22/2013	Q313	$1.40	$1.50	$739.12 million	$758.00 million	View	Listen
7/23/2013	Q2 2013	$1.38	$1.42	$750.91 million	$759.90 million	View	Listen
4/23/2013	Q1 2013	$1.42	$1.44	$728.45 million	$740.30 million	View	Listen
1/31/2013	Q4 2012	$1.67	$1.70	$757.49 million	$762.60 million	View	Listen
10/23/2012		$1.64	$1.64			View	N/A
7/25/2012		$1.64	$1.62			View	N/A
4/24/2012	Q1 2012	$1.57	$1.61			View	N/A
1/31/2012		$1.68	$1.70			View	N/A
10/25/2011		$1.60	$1.62			View	N/A
7/21/2011		$1.57	$1.57			View	N/A
4/21/2011		$1.46	$1.51			View	N/A
1/31/2011		$1.48	$1.54			View	N/A
10/21/2010	Q3 2010	$1.40	$1.43			View	N/A
7/22/2010	Q2 2010	$1.36	$1.39			View	N/A
4/22/2010	Q1 2010	$1.24	$1.25			View	N/A
1/28/2010	Q4 2009	$1.34	$1.39			View	N/A
10/21/2009	Q3 2009	$1.27	$1.31			View	N/A
7/22/2009	Q2 2009	$1.21	$1.23			View	N/A
4/22/2009	Q1 2009	$1.17	$1.17			View	N/A
1/29/2009	Q4 2008	$1.18	$1.19			View	N/A
10/22/2008	Q3 2008	$1.08	$1.10			View	N/A
7/23/2008	Q2 2008	$1.08	$1.10			View	N/A
4/23/2008	Q1 2008	$1.05	$1.06			View	N/A
1/31/2008	Q4 2007	$0.99	$1.01			View	N/A

(Earnings results data provided by Zacks Investment Research)

C R Bard (NYSE:BCR) Dividend Information

C R Bard pays an annual dividend of $0.78 per share, with a dividend yield of 0.24%. BCR's most recent quarterly dividend payment was Friday, December 29. The company has grown its dividend for the last 46 consecutive years and is increasing its dividend by an average of 6.50% each year.

Most Recent Dividend:	12/29/2017
Annual Dividend:	$0.78
Dividend Yield:	0.24%
Dividend Growth:	6.50% (3 Year Average)
Payout Ratio:	6.56% (Based on This Year's Estimates) 6.01% (Based on Next Year's Estimates)
Track Record:	46 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for C R Bard (NYSE:BCR)

C R Bard (NYSE:BCR) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/11/2017	quarterly	$0.26	0.32%	12/7/2017	12/8/2017	12/29/2017
6/14/2017	quarterly	$0.26	0.33%	7/20/2017	7/24/2017	8/4/2017
4/19/2017	quarterly	$0.26	0.41%	4/27/2017	5/1/2017	5/12/2017
12/14/2016	quarterly	$0.26	0.47%	1/19/2017	1/23/2017	2/3/2017
10/12/2016	quarterly	$0.26	0.48%	10/20/2016	10/24/2016	11/4/2016
6/8/2016	quarterly	$0.26	0.46%	7/14/2016	7/18/2016	7/29/2016
4/20/2016	quarterly	$0.24	0.46%	4/28/2016	5/2/2016	5/13/2016
12/9/2015	quarterly	$0.24	0.52%	1/21/2016	1/25/2016	2/5/2016
10/14/2015	quarterly	$0.24	0.5%	10/22/2015	10/26/2015	11/6/2015
6/10/2015	quarterly	$0.24	0.56%	7/16/2015	7/20/2015	7/31/2015
4/15/2015	quarterly	$0.22	0.52%	4/23/2015	4/27/2015	5/8/2015
12/10/2014	quarterly	$0.22	0.52%	1/22/2015	1/26/2015	2/6/2015
10/8/2014	quarterly	$0.22	0.59%	10/16/2014	10/20/2014	10/31/2014
6/11/2014	quarterly	$0.22	0.62%	7/17/2014	7/21/2014	8/1/2014
4/16/2014	quarterly	$0.21	0.6%	4/24/2014	4/28/2014	5/9/2014
12/11/2013	quarterly	$0.21	0.63%	1/16/2014	1/21/2014	1/31/2014
10/9/2013	quarterly	$0.21	0.72%	10/17/2013	10/21/2013	11/1/2013
6/12/2013	quarterly	$0.21	0.77%	7/18/2013	7/22/2013	8/2/2013
4/17/2013	quarterly	$0.20	0.8%	4/25/2013	4/29/2013	5/10/2013
12/12/2012	quarterly	$0.20	0.83%	1/17/2013	1/22/2013	2/1/2013

(Data available from 1/1/2013 forward)

C R Bard (NYSE BCR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 79.11%

Insider Trading History for C R Bard (NYSE:BCR)

C R Bard (NYSE BCR) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/20/2017	John A. Deford	VP	Sell	14,107	$333.48	$4,704,402.36
12/14/2017	Jim C Beasley	Insider	Sell	3,395	$332.00	$1,127,140.00	25,630
12/11/2017	Jim C Beasley	Insider	Sell	15,044	$332.00	$4,994,608.00
11/7/2017	John H Weiland	Vice Chairman	Sell	33,435	$333.31	$11,144,219.85	76,331
11/2/2017	Christopher S. Holland	Insider	Sell	38,242	$334.04	$12,774,357.68
11/2/2017	Frank Lupisella Jr	VP	Sell	7,035	$334.70	$2,354,614.50	13,824
10/30/2017	David M. Barrett	Director	Sell	3,344	$327.31	$1,094,524.64
10/20/2017	Betty D Larson	VP	Sell	5,906	$330.16	$1,949,924.96	10,753
10/18/2017	Frank Lupisella, Jr.	VP	Sell	9,173	$325.00	$2,981,225.00
10/12/2017	Timothy P Collins	Insider	Sell	55,818	$322.03	$17,975,070.54
10/9/2017	Timothy P Collins	Insider	Sell	8,388	$322.00	$2,700,936.00
9/29/2017	Sharon M. Luboff	Insider	Sell	30,252	$320.00	$9,680,640.00
8/10/2017	John P Groetelaars	Insider	Sell	23,687	$318.73	$7,549,757.51	31,445
4/24/2017	Frank Lupisella Jr	VP	Sell	3,622	$304.00	$1,101,088.00	10,139
2/21/2017	Jim C Beasley	Insider	Sell	4,390	$245.00	$1,075,550.00	26,625
2/14/2017	John A Deford	VP	Sell	2,788	$240.51	$670,541.88	24,684
2/14/2017	John H Weiland	Vice Chairman	Sell	14,091	$240.49	$3,388,744.59	68,978
2/14/2017	John P Groetelaars	Insider	Sell	732	$240.49	$176,038.68	19,695
2/14/2017	Timothy M Ring	Chairman	Sell	14,425	$240.50	$3,469,212.50	100,283
2/13/2017	John A. Deford	VP	Sell	469	$240.07	$112,592.83
2/13/2017	John H Weiland	Vice Chairman	Sell	1,274	$240.00	$305,760.00	70,033
2/13/2017	Timothy M Ring	Chairman	Sell	1,767	$240.02	$424,115.34	103,906
2/13/2017	Timothy P Collins	Insider	Sell	642	$240.30	$154,272.60	34,515
2/10/2017	Betty D Larson	VP	Sell	3,292	$240.92	$793,108.64	8,399
2/9/2017	Jim C Beasley	Insider	Sell	8,593	$239.58	$2,058,710.94	34,415
2/9/2017	John A. Deford	VP	Sell	5,816	$239.58	$1,393,397.28
2/9/2017	John H Weiland	Vice Chairman	Sell	14,281	$239.54	$3,420,870.74	83,613
2/9/2017	Timothy M Ring	Chairman	Sell	20,324	$239.56	$4,868,817.44	127,954
1/31/2017	Gail K Naughton	Director	Sell	367	$236.22	$86,692.74	1,620
1/11/2017	John P Groetelaars	Insider	Sell	573	$235.00	$134,655.00	16,554
1/10/2017	Frank Lupisella, Jr.	VP	Sell	2,945	$232.00	$683,240.00
1/9/2017	Frank Lupisella, Jr.	VP	Sell	210	$232.00	$48,720.00
12/30/2016	Frank Lupisella Jr	VP	Sell	237	$226.00	$53,562.00	14,520
12/30/2016	Jim C Beasley	Insider	Sell	4,709	$225.00	$1,059,525.00	27,378
12/12/2016	John A. Deford	VP	Sell	15,883	$218.03	$3,462,970.49
12/12/2016	John H Weiland	Vice Chairman	Sell	11,190	$219.67	$2,458,107.30	72,780
12/12/2016	Sharon M. Luboff	Insider	Sell	6,000	$219.00	$1,314,000.00
10/28/2016	Christopher S. Holland	Insider	Sell	5,724	$211.12	$1,208,450.88
9/28/2016	Timothy M Ring	Chairman	Sell	92,293	$227.81	$21,025,268.33	145,876
9/26/2016	Timothy M Ring	Chairman	Sell	110,000	$228.96	$25,185,600.00	96,030
9/19/2016	Betty D Larson	VP	Sell	4,032	$225.33	$908,530.56	10,298
9/6/2016	John A. Deford	VP	Sell	7,928	$221.06	$1,752,563.68
5/27/2016	Christopher S Holland	CFO	Sell	3,970	$219.89	$872,963.30	31,306
5/17/2016	John P Groetelaars	Insider	Sell	1,162	$219.88	$255,500.56	17,431
5/12/2016	Tommy G Thompson	Director	Sell	500	$219.52	$109,760.00	7,036
5/5/2016	Tony L White	Director	Sell	1,200	$216.19	$259,428.00	14,671
4/28/2016	Jim C Beasley	Insider	Sell	4,709	$215.00	$1,012,435.00	27,378
4/27/2016	Sharon M Luboff	VP	Sell	10,000	$210.00	$2,100,000.00	33,706
3/29/2016	Christopher S Holland	CFO	Sell	1,650	$200.00	$330,000.00	27,335
2/25/2016	Jim C Beasley	Insider	Sell	1,113	$195.27	$217,335.51	22,669
2/23/2016	Frank Lupisella Jr	VP	Sell	2,300	$190.25	$437,575.00	14,495
2/22/2016	Christopher S Holland	CFO	Sell	618	$190.00	$117,420.00	28,985
2/22/2016	Patricia G Christian	VP	Sell	3,182	$190.00	$604,580.00	9,240
2/17/2016	John A. Deford	VP	Sell	661	$187.44	$123,897.84	21,607
2/17/2016	John H. Weiland	COO	Sell	1,618	$187.45	$303,294.10	61,590
2/17/2016	Timothy M. Ring	CEO	Sell	2,453	$187.62	$460,231.86	97,370
2/17/2016	Timothy P. Collins	insider	Sell	974	$187.48	$182,605.52	29,276
2/16/2016	Anthony Welters	Director	Sell	1,784	$187.47	$334,446.48	1,908
2/12/2016	Christopher S. Holland	CFO	Sell	6,297	$181.08	$1,140,260.76	29,603
2/12/2016	John A. Deford	VP	Sell	6,400	$182.40	$1,167,360.00	22,855
2/12/2016	John H. Weiland	COO	Sell	15,632	$182.86	$2,858,467.52	64,603
2/12/2016	Timothy M. Ring	CEO	Sell	24,003	$182.76	$4,386,788.28	102,200
2/12/2016	Timothy P. Collins	insider	Sell	7,893	$182.28	$1,438,736.04	31,435
2/10/2016	John P. Groetelaars	insider	Sell	3,319	$187.16	$621,184.04	18,841
2/9/2016	John A. Deford	VP	Sell	3,407	$180.62	$615,372.34	18,710
2/9/2016	John H. Weiland	COO	Sell	8,898	$181.10	$1,611,427.80	53,078
2/9/2016	Timothy M. Ring	CEO	Sell	4,836	$181.20	$876,283.20	93,896
2/9/2016	Timothy P. Collins	insider	Sell	4,205	$181.24	$762,114.20	25,076
2/2/2016	Tommy G Thompson	Director	Sell	2,319	$188.75	$437,711.25	6,536
12/16/2015	John H. Weiland	COO	Sell	19,686	$188.49	$3,710,614.14	67,409
12/16/2015	Patricia G Christian	VP	Sell	1,908	$190.00	$362,520.00	9,413
12/14/2015	Jim C. Beasley	insider	Sell	20,577	$184.78	$3,802,218.06	24,313
12/14/2015	John A. Deford	VP	Sell	5,627	$184.00	$1,035,368.00	23,646
12/14/2015	John H. Weiland	COO	Sell	33,569	$184.25	$6,185,088.25	73,505
11/30/2015	Timothy M. Ring	CEO	Sell	22,052	$187.37	$4,131,883.24	119,694
10/29/2015	Timothy M. Ring	CEO	Sell	30,543	$184.79	$5,644,040.97	119,694
10/27/2015	Gail K. Naughton	Director	Sell	2,458	$181.99	$447,331.42	1,556
9/29/2015	Timothy M. Ring	CEO	Sell	40,000	$185.16	$7,406,400.00	119,694
8/31/2015	Timothy M. Ring	CEO	Sell	40,000	$195.17	$7,806,800.00	119,694
8/18/2015	Sharon M. Luboff	VP	Sell	2,374	$199.76	$474,230.24	28,399
8/17/2015	Sharon M Luboff	VP	Sell	2,030	$200.00	$406,000.00
8/14/2015	Tommy G Thompson	Director	Sell	1,200	$199.25	$239,100.00
7/13/2015	John P Groetelaars	Insider	Sell	2,456	$175.00	$429,800.00
7/13/2015	Timothy M Ring	CEO	Sell	20,000	$176.04	$3,520,800.00
4/28/2015	Tommy G Thompson	Director	Sell	1,200	$170.43	$204,516.00
3/23/2015	Timothy M Ring	CEO	Sell	7,628	$170.65	$1,301,718.20
2/23/2015	Timothy M Ring	CEO	Sell	20,000	$176.33	$3,526,600.00
2/19/2015	Jim C Beasley	Insider	Sell	2,884	$174.79	$504,094.36
2/19/2015	John H Weiland	COO	Sell	8,413	$174.99	$1,472,190.87
2/19/2015	John P Groetelaars	VP	Sell	4,566	$175.14	$799,689.24
2/17/2015	Jim C Beasley	Insider	Sell	9,904	$174.58	$1,729,040.32
2/17/2015	John A Deford	VP	Sell	6,146	$174.58	$1,072,968.68
2/17/2015	John H Weiland	COO	Sell	13,616	$174.51	$2,376,128.16
2/17/2015	Timothy M Ring	CEO	Sell	6,284	$174.75	$1,098,129.00
2/12/2015	Patricia G Christian	VP	Sell	1,408	$173.97	$244,949.76
2/12/2015	Timothy M Ring	CEO	Sell	14,363	$173.74	$2,495,427.62
2/12/2015	Timothy P Collins	Insider	Sell	6,564	$174.00	$1,142,136.00
2/9/2015	Anthony Welters	Director	Sell	1,563	$169.02	$264,178.26
1/22/2015	Timothy M Ring	CEO	Sell	20,000	$177.84	$3,556,800.00
12/22/2014	Timothy M Ring	CEO	Sell	32,325	$169.64	$5,483,613.00
12/17/2014	Jim C Beasley	Insider	Sell	4,525	$168.42	$762,100.50
12/17/2014	Sharon M Luboff	VP	Sell	3,564	$168.36	$600,035.04
12/16/2014	Jim C Beasley	Insider	Sell	14,634	$167.47	$2,450,755.98
12/16/2014	John A Deford	VP	Sell	5,626	$167.47	$942,186.22
12/16/2014	John H Weiland	COO	Sell	23,093	$166.74	$3,850,526.82
12/16/2014	Timothy M Ring	CEO	Sell	15,232	$166.60	$2,537,651.20
12/15/2014	John H Weiland	COO	Sell	13,589	$166.56	$2,263,383.84
12/10/2014	Patricia G Christian	VP	Sell	1,269	$169.20	$214,714.80
12/9/2014	John H Weiland	COO	Sell	6,350	$170.32	$1,081,532.00
12/9/2014	Timothy M Ring	CEO	Sell	9,550	$170.20	$1,625,410.00
10/27/2014	Sharon M Luboff	VP	Sell	10,000	$158.80	$1,588,000.00
10/22/2014	Timothy M Ring	CEO	Sell	60,000	$149.07	$8,944,200.00
10/6/2014	Timothy M Ring	CEO	Sell	60,000	$148.00	$8,880,000.00
9/10/2014	John H Weiland	COO	Sell	27,179	$149.50	$4,063,260.50
9/2/2014	Timothy M Ring	CEO	Sell	10,228	$148.83	$1,522,233.24
8/4/2014	Bronwen K Kelly	VP	Sell	10,055	$150.25	$1,510,763.75
8/1/2014	Timothy M Ring	CEO	Sell	10,231	$149.04	$1,524,828.24
7/30/2014	Timothy P Collins	Insider	Sell	30,914	$150.38	$4,648,847.32
7/29/2014	Sharon M Luboff	VP	Sell	5,115	$151.37	$774,257.55
7/1/2014	Timothy M Ring	CEO	Sell	10,231	$144.30	$1,476,333.30
6/2/2014	Timothy M Ring	CEO	Sell	10,231	$147.50	$1,509,072.50
3/3/2014	Timothy Ring	CEO	Sell	10,231	$142.23	$1,455,155.13	172,216
2/27/2014	Sharon Luboff	VP	Sell	9,914	$144.86	$1,436,142.04	36,958
2/20/2014	Frank Lupisella, Jr.	VP	Sell	2,520	$140.26	$353,455.20	18,122
2/18/2014	Marc Breslawsky	Director	Sell	2,400	$141.34	$339,216.00	12,914
2/11/2014	John Weiland	COO	Sell	9,328	$135.32	$1,262,264.96	115,695
2/11/2014	Sharon Luboff	VP	Sell	1,400	$135.00	$189,000.00	39,357
1/16/2014	John Weiland	COO	Sell	81,500	$136.13	$11,094,595.00	133,483
1/13/2014	Sharon Luboff	VP	Sell	2,500	$135.00	$337,500.00	42,381
12/12/2013	Jim Beasley	Insider	Sell	9,802	$133.98	$1,313,271.96	39,493
12/12/2013	John Deford	VP	Sell	2,792	$133.98	$374,072.16	33,543
12/10/2013	John Weiland	COO	Sell	10,389	$137.30	$1,426,409.70	123,994
12/10/2013	Timothy Ring	CEO	Sell	15,623	$137.12	$2,142,225.76	178,568
12/2/2013	Timothy Ring	CEO	Sell	10,231	$138.85	$1,420,574.35	209,323
11/6/2013	David Barrett	Director	Sell	1,600	$138.13	$221,008.00	2,547
10/28/2013	Herbert L Henkel	Director	Sell	2,400	$134.66	$323,184.00
10/28/2013	Sharon M Alterio	VP	Sell	14,002	$134.91	$1,889,009.82
10/23/2013	John H Weiland	COO	Sell	60,210	$134.01	$8,068,742.10
10/21/2013	John H Weiland	COO	Sell	84,525	$125.62	$10,618,030.50
10/21/2013	Timothy M Ring	CEO	Sell	8,313	$125.52	$1,043,447.76
10/18/2013	Gary D Dolch	VP	Sell	10,000	$125.00	$1,250,000.00
9/24/2013	Timothy Ring	CEO	Sell	8,313	$117.77	$979,022.01	209,323
9/9/2013	John A Deford	VP	Sell	28,364	$117.89	$3,343,831.96
9/3/2013	Timothy Ring	CEO	Sell	10,231	$114.65	$1,172,984.15	209,323
8/30/2013	Jim Beasley	Insider	Sell	1,420	$115.33	$163,768.60	41,022
8/21/2013	Timothy Ring	CEO	Sell	8,313	$113.24	$941,364.12	209,323
8/12/2013	Sharon Alterio	VP	Sell	13,379	$117.01	$1,565,476.79	47,032
8/5/2013	Brian P Kelly	VP	Sell	28,000	$115.69	$3,239,320.00
8/2/2013	David M Barrett	Director	Sell	1,200	$115.70	$138,840.00
8/2/2013	Frank Lupisella Jr	VP	Sell	10,500	$115.61	$1,213,905.00
8/1/2013	John H Weiland	COO	Sell	87,336	$115.35	$10,074,207.60
7/29/2013	Timothy P Collins	Insider	Sell	22,025	$113.60	$2,502,040.00
7/26/2013	Anthony Welters	Director	Sell	5,600	$113.12	$633,472.00
7/26/2013	Jean F Holloway	VP	Sell	2,275	$113.52	$258,258.00
7/22/2013	Timothy M Ring	CEO	Sell	8,312	$113.58	$944,076.96
6/21/2013	Timothy M Ring	CEO	Sell	8,312	$110.05	$914,735.60
6/20/2013	Gary D Dolch	VP	Sell	14,569	$109.97	$1,602,152.93
5/21/2013	Timothy M Ring	CEO	Sell	8,312	$106.65	$886,474.80
5/20/2013	Marc C Breslawsky	Director	Sell	2,400	$107.20	$257,280.00
5/8/2013	Timothy M Ring	CEO	Sell	8,312	$102.00	$847,824.00
4/11/2013	G Mason Morfit	Insider	Sell	300,000	$102.47	$30,741,000.00
4/9/2013	Timothy M Ring	CEO	Sell	8,312	$102.00	$847,824.00

(Data available from 1/1/2013 forward)

C R Bard (NYSE BCR) News Headlines

Source:

Date	Headline
	C R Bard (BCR) Receives Hold Rating from BMO Capital Markets www.americanbankingnews.com - April 19 at 5:50 PM
	C R Bard (BCR) Downgraded by Zacks Investment Research to Hold www.americanbankingnews.com - April 17 at 10:55 PM
	C R Bard (BCR) Downgraded by BidaskClub to Buy www.americanbankingnews.com - April 17 at 4:17 PM
	C R Bard's (BCR) Hold Rating Reiterated at Jefferies Group www.americanbankingnews.com - April 13 at 11:42 PM
	Hernia Mesh Lawsuit Plaintiffs Seek MDL for Product Liability Claims Involving C.R. Bard's Polypropylene Devices, Bernstein Liebhard LLP Reports www.prnewswire.com - April 13 at 3:37 PM
	Analyzing C R Bard (BCR) and LDR (LDRH) www.americanbankingnews.com - March 31 at 7:04 AM
	Head-To-Head Review: C R Bard (BCR) versus Palomar Medical Technologies (PMTI) www.americanbankingnews.com - March 29 at 3:24 AM
	Contrasting Given Imaging (GIVN) and C R Bard (BCR) www.americanbankingnews.com - March 18 at 5:16 AM
	C R Bard Inc (BCR) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - March 7 at 1:50 PM
	Becton Dickinson Has A Strong, Diverse Pipeline, But Is Fairly Valued, Says BMO finance.yahoo.com - March 6 at 4:54 PM
	Contrasting Intersect ENT (XENT) and C R Bard (BCR) www.americanbankingnews.com - February 17 at 3:06 AM
	C R Bard Inc (BCR) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - February 10 at 1:38 PM
	C R Bard Inc (BCR) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - January 16 at 1:40 PM
	KeyBanc Initiates Becton, Dickinson And Co. With Bullish Stance - Benzinga www.benzinga.com - January 5 at 1:10 PM
	C.R. Bard, Inc. -- Moody's withdraws C.R. Bard's ratings finance.yahoo.com - January 2 at 11:00 AM
	ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 29, 2017 finance.yahoo.com - December 29 at 3:45 PM
	BD And Bard Expect Proposed Acquisition To Close On Dec. 29 www.nasdaq.com - December 29 at 11:13 AM
	BD Completes Bard Acquisition, Creating New Global Health Care Leader finance.yahoo.com - December 29 at 11:13 AM
	BD Statement On MOFCOM Clearance Of Bard Acquisition finance.yahoo.com - December 28 at 2:21 PM
	NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018 finance.yahoo.com - December 28 at 2:21 PM
	Becton, Dickinson and Company -- Moody's downgrades Becton, Dickinson and Company to speculative grade finance.yahoo.com - December 28 at 2:21 PM
	Analysts Anticipate C.R. Bard, Inc. (BCR) Will Post Earnings of $3.09 Per Share www.americanbankingnews.com - December 28 at 8:18 AM
	Becton, Dickinson (BDX) a Step Closer to Bard Acquisition finance.yahoo.com - December 27 at 11:40 AM
	C.R. Bard (BCR) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - December 26 at 6:28 PM
	C.R. Bard, Inc. (New Jersey) – Value Analysis (NYSE:BCR) : December 26, 2017 finance.yahoo.com - December 26 at 4:16 PM
	FTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson (BDX) Acquiring C. R. Bard, Inc. (BCR) www.streetinsider.com - December 23 at 3:17 AM
	C.R. Bard, Inc. (BCR) VP John A. Deford Sells 14,107 Shares www.americanbankingnews.com - December 22 at 5:38 PM
	Stock Review for Medical Supplies Investors -- CR Bard, Glaukos, Waters, and Cooper - PR Newswire (press release) www.prnewswire.com - December 22 at 5:06 PM
	FTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson (BDX) Acquiring CR ... - StreetInsider.com www.streetinsider.com - December 22 at 5:06 PM
	BD Statement On FTC Clearance Of Bard Acquisition finance.yahoo.com - December 22 at 5:06 PM
	C.R. Bard, Inc. (BCR) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - December 22 at 2:50 PM
	C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bearish Manner : BCR-US : December 22, 2017 finance.yahoo.com - December 22 at 11:26 AM
	C.R. Bard, Inc. (BCR) Insider Sells $1,127,140.00 in Stock www.americanbankingnews.com - December 18 at 8:36 PM
	ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 18, 2017 finance.yahoo.com - December 18 at 3:45 PM
	C.R. Bard, Inc. (BCR) Insider Sells $4,994,608.00 in Stock www.americanbankingnews.com - December 13 at 5:26 PM
	C.R. Bard, Inc. (BCR) Expected to Announce Quarterly Sales of $1.02 Billion www.americanbankingnews.com - December 13 at 12:34 PM
	Zacks: Brokerages Expect C.R. Bard, Inc. (BCR) to Post $3.11 Earnings Per Share www.americanbankingnews.com - December 11 at 1:24 AM
	C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : December 08th, 2017 (record date) : By the numbers : December 8, 2017 finance.yahoo.com - December 8 at 11:30 AM
	ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 7, 2017 finance.yahoo.com - December 7 at 3:53 PM
	C.R. Bard (BCR) Downgraded to "Hold" at ValuEngine www.americanbankingnews.com - December 3 at 10:04 PM
	How Does C R Bard Inc’s (BCR) EPS Growth Stack Up Against Industry Performance? finance.yahoo.com - December 3 at 3:46 PM
	Financial Comparison: C.R. Bard (BCR) & Sientra (SIEN) www.americanbankingnews.com - December 2 at 11:28 AM
	ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 27, 2017 finance.yahoo.com - November 27 at 5:12 PM
	C.R. Bard, Inc. (BCR) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - November 27 at 12:34 PM
	Paul Tudor Jones: The Global Macro Trader finance.yahoo.com - November 25 at 3:37 PM
	Brokerages Expect C.R. Bard, Inc. (BCR) Will Post Quarterly Sales of $1.02 Billion www.americanbankingnews.com - November 25 at 9:44 AM
	C.R. Bard, Inc. (BCR) Expected to Announce Earnings of $3.12 Per Share www.americanbankingnews.com - November 23 at 3:10 AM
	CR Bard (BCR) a Strong Buy on Outstanding Quant Score - Investorplace.com investorplace.com - November 21 at 4:56 PM
	CR Bard (BCR) a Strong Buy on Outstanding Quant Score investorplace.com - November 21 at 12:06 PM
	BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines finance.yahoo.com - November 16 at 11:54 AM

C R Bard (NYSE:BCR) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

C R Bard (NYSE:BCR) Income Statement, Balance Sheet and Cash Flow Statement

C R Bard (NYSE BCR) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff